

BAB V

KESIMPULAN DAN SARAN

A. KESIMPULAN

Berdasarkan hasil penelitian dapat disimpulkan bahwa :

1. Berdasarkan penelitian yang telah dilakukan pola persepan di klinik Apotek Talenta Surakarta tahun 2018 telah sesuai penggambaran obat dan jenis obat dengan pedoman KEMENKES RI Nomor 364/MENKES/SK/2009 tentang Pedoman Penanggulangan TBC.
2. Penggunaan OAT pada pasien Tuberkulosis Paru di klinik Apotek Talenta Surakarta Tahun 2018 telah sesuai dengan KEMENKES RI Nomor 364/MENKES/SK/2009 tentang Pedoman Penanggulangan TBC.
3. Penggunaan OAT sudah rasional meliputi tepat indikasi, tepat obat, tepat dosis dan tepat pasien untuk terapi Tuberkulosis Paru di klinik Apotek Talenta Surakarta Tahun 2018 dibuktikan dengan pasien sembuh dengan kenaikan berat badan dan hasil toraks.

B. SARAN

Berdasarkan penelitian yang telah dilakukan, maka dapat disimpulkan hal-hal sebagai berikut :

1. Peneliti mengharapkan hasil pengobatan yang menyatakan sembuh pada pasien TBC tidak hanya dipakai foto toraks saja tapi juga hasil BTA.
2. Perlu dilakukan penelitian lebih lanjut mengenai kesesuaian pemilihan OAT berdasarkan waktu pemberian obat serta resistensi dalam pemakaian OAT.

DAFTAR PUSTAKA

- Aprilia Sudi Rizkiyani, 2015. Profil Peresepan Obat Tuberkulosis Di Rumah Sakit Paru, Kota Batu (skripsi), Malang : Fakultas Ilmu Kesehatan, UMM.
- Aldy Rian Saputra, 2015. Kudus : Fakultas Farmasi, Universitas Muria.
- AS. Sulistyowati, 2017. Yogyakarta : Universitas Sanata Dharma. – Core.ac.uk.
- B Kurniawati, 2019. Pola Peresepan Obat Anti Tuberkulosis di Poli TB DOTS RSUD Tidar Kota Magelang Bulan januari – Juni 2018. Repository.setiabudi.ac.id.
- Diana Nurullah, 2018. Analisa sel monosit pada darah penderita TBC di RS Khusus Paru Medan 2018. Universitas Sari Mutiara Indonesia.
- Dinas Kesehatan Bantul, 2016. Peubahan Rencana Strategis Dinas Kesehatan 2016-2021.
- Dinas Kesehatan Propinsi Jawa Tengah, 2016. Profil Kesehatan Propinsi Jawa Tengah 2016.
- Dinas Kesehatan Kota Surakarta, 2019. <https://solo.tribunnews.com> .>.
- Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke G.R., Wells, B.G., and Posey, L.M., 2008 *Pharmacotherapy : A Patophysiologic Approach*, 7th Edition, The McGraw-H Companies, United State of America, p. 1840.
- Giri Tri Cahyono, 2014. Evaluasi Ketepatan Terapi terhadap Keberhasilan Terapi pada Pasien Tuberkulosis di Balai Besar Kesehatan Paru Masyarakat Surakarta (Skripsi). Surakarta : Fakultas Farmasi, Universitas Muhammadiyah.
- Hidayat, 2009. Metode Penelitian.
- Jamayanti, Lia. 2014. Karakteristik Penderita Tuberkulosis Paru Di Poliklinik Paru Rumah Sakit Umum Daerah Dr. Zainoel Abidin Banda Aceh Periode Januari 2014 – Mei 2014. Elektronik Theses And Disertations Unsiyah.
- Kementrian Kesehatan Republik Indonesia, 2009. Pedoman Penanggulangan TBC.
- Kementrian Kesehatan Republik Indonesia, 2015. Rencana Strategis Kementrian Kesehatan Tahun 2015-2019.
- Kementrian Kesehatan Republik Indonesia, 2018. Pencegahan Dan Pengendalian Penyakit.
- Laily, D. W, Rombot, D., Lampus, B. 2015 Karakteristik Pasien Tuberkulosis Paru Di Puskesmas Tumintang Manado. Jurnal Kedokteran Komunitas Dan Tropis Vol 3(1):1-5.

- Lienhardt, C; Ccok.S.V.,Burgos, M.,Yorkeeddwards,V., Rogouts, L.,Anyo,G,Kims. J., Jindani, A., Enarson, D.A.&Nunn,A.J2011.*Efficacy and safety of a \$4-drug-fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis the study c randomized controlled trial*. American medical association,305,1415-1423.
- Marline Abdassah dan Alda Anjella Lady Carina Paska Agatha, 2019. Faktor Yang Mempengaruhi Kepatuhan Pasien Dalam Pengobatan TBC Paru. Farmaka, 7(2), 385-389. Journal. Unpad.ac.id.
- Musdalipah, Eni Nur Hikma, Karmilah, Muh. Fakhrurazi, 2018. JURNAL ILMIAH MANUNTUNG, 4(1), 67-73, 2018. P-ISSN.2443-115x.e-ISSN.2477-1821.
- M prananda-farmasi Fakultas Kedokteran 2016-jurnal.untan.ac.id.
- Nurfa Rahmayanti, 2017. Evaluasi Penggunaa Obat Anti Tuberkulosis pada pasien Tuberkulosis Paru di Rumah Sakit Umum Daerah Pandan Anyar Boyolali Tahun 2016 (Skripsi). Surakarta : Fakultas Farmasi, Universitas Setia Budi.
- Ratna Indrayani dan SKp Arum Pratiwi, 2011 Kecemasan Pasien TB Paru ditinjau dari Lama Konsumsi Obat TBC di Wilayah Kerja Puskesmas Gemolong Sragen (Skripsi). Surakarta : Universitas Muhammadiyah.
- Sawitri Avica dan Wisnu Kundarto, 2018. Evaluasi Ketepatan Obat dan Dosis Obat Anti Tuberkulosis pada Pasien Anak di Instalasi Rawat jalan RSUD Dr Moewardi Surakarta Periode 2016-2017. Journal of Pharmaceutical Science and Clinical Research, 2018, 02, 93-103. DOI : 10.20961/jpscr.v3i2.22200.
- Setiyani Dewi Untari, 2018. Evaluasi Rasionalitas Penggunaan Obat Anti Tuberkulosis pada pasien Rawat Inap TB MDR (Tuberculosis Multi Drug Resistance) Dewasa di RSUD DR Moewardi Surakarta Tahun 2016.(Skripsi). Surakarta : Universitas Muhammadiyah.
- Sofa D. Alfian, Eva S. Tarigan., Irma M. Puspitasari, Rizky Abdulah, 2012. Profil penggunaan Antituberkulosis di Apotek di Kota Bandung Periode 2008-2010. Fakultas Farmasi Universitas Padjajaran, Sumedang, Indonesia. Jurnal Farmasi Klinik Indonesia. Vol 1 no 4 Desember 2012.
- Sri Andayani dan Yoni Astuti, 2017. Prediksi Kejadian Penyakit Tuberkulosis Paru berdasarkan Usia di kabupaten Ponorogo Tahun 2016-2020. Program Studi Keperawatan, Universitas Muhammadiyah Ponorogo. Program Studi Keperawatan, Universitas Muhammadiyah Yogyakarta. Indonesia Journal for Health Science. Vol.01,No.02,September 2017, Hal 29-33 ISSN 2549-2721(print), ISSN 2549-2748(Online).

LAMPIRAN
REKAPITULASI DATA PENGAMBILAN SAMPEL

NO	NO. REK	NAMA PASIEN	JENIS KELAMIN		UMUR	BERAT BADAN	DIAGNOSIS	TERAPI OBAT		RASIONALITAS		
			L	P				NAMA OBAT	DOSIS	TEPAT	TEPAT	TEPAT
										INDIKASI	OBAT	DOSIS
1	C/31/XII/17	NY. CMH		1	74	44	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								ISONIAZIDE 300 mg	1-0-0			
								PYRAZINAMIDE 500 mg	2-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
2	J/48/X/17	BP. JPR	1		58	50	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								LEVOFLOXACIN 500 mg	1-0-0			
3	N/105/XII/17	SDR. NFL	1		12	58	TBC	RIFASTAR	1-0-0	1	1	1
4	SA/71/XII/15	SDR.STW	1		26	86	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								ISONIAZIDE 300 mg	1-0-0			
								PYRAZINAMIDE 500 mg	2-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
5	P/37/X/17	BP.PWD	1		35	60	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			

6	SU/141/IX/17	BP. SPT	1		66	65	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
7	A/85/IV/16	SDR. AMZ	1		12	31	TBC	RIFAMPICIN 300 mg	1-0-0	1	1	1
								ISONIAZIDE 300 mg	1-0-0			
								VIT B6	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
8	R/45/VI/17	BP. RT	1		33	83	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2 1/2 -0-0			
9	D/4/I/18	NY.DY		1	44	49	TBC	PRO TB 4	3-0-0	1	1	1
10	E/37/IV/17	NY.EDG		1	42	66	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
11	MU/3/I/18	SDR.MI	1		25	48	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								ISONIAZIDE 300 mg	1-0-0			
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
								ETHAMBUTOL 500 mg	2-0-0			
12	W/61/X/17	BP.WW	1		22	55	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
13	SU/192/XII/17	BP.SMN	1		72	47,5	TBC	PRO TB 4	1 dd III	1	1	1
14	V/4/II/15	NY. VH		1	30	49	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			

								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
15	Y/57/XI/17	BP. YL	1		42	62	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
16	W/18/III/17	BP. WDY	1		46	94	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
17	O/14/XII/17	SDR. OA	1		22	43,5	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
18	R/6/I/8	NY.RMN		1	59	35	TBC	PRO TB 4	2-0-0	1	1	1
19	MA/22/V/17	BP. MS	1		72	41	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								TIBITOL	1 1/2-0-0			
20	SA/47/X/17	BP. SDM	1		50	50	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
21	T/8/I/18	BP. TM	1		47	79	TBC	PRO TB 4	4-0-0	1	1	1
22	D/6/I/18	NN. DA		1	21	38	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	0-1 1/2-0			

								PYRAZINAMIDE 500 mg	0-0-2			
23	K/41/VII/17	BP. KR	1		81	40	TBC	INH 300 mg	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								NEOTIBI	0-0-2			
24	F/48/X/17	NY. FN		1	50	40	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
25	SR/73/XI/17	NY. SS		1	58	67	TBC	INHA 400	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
26	E/83/XI/17	BP. ED	1		76	54	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
27	L/47/X/17	NY. LE		1	32	51	TBC	INH 300 mg	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
28	L/54/IV/18	BP. LW	1		38	53	TBC	MERIMAC 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	2 1/2 -0-0			
29	T/34/V/17	NY. TMN		1	27	40	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
30	K/65/XI/17	BP. KY	1		58	50	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			

31	N/93/XI/17	NY. NN		1	33	39	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
32	A/207/XI/17/	BP. AK	1		36	57	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
33	K/42/I/14	SDR. KV	1		28	55	TBC	PRO TB 4	3-0-0	1	1	1
34	R/21/I/17	BP. RDK	1		30	62	TBC	INHA 400	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
35	D/15/II/18	SDR. DJ	1		15	50	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
36	A/82/IV/17	BP. AS	1		29	46	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
37	SU/6/I/18	BP. SWD	1		58,5	73	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
38	N/102/XII/17	NY. NM		1	34	54	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			

39	D/88/XI/17	NY. DR		1	63	57	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-3-0			
40	B/10/II/18	BP. BS	1		56	45	TBC	RIFAMPICIN 300 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								TIBITOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
41	A/165/IX/17	BP. AN	1		24	53	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
42	E/76/XI/16	NN. UNK		1	29	33	TBC	RIFAMPICIN 300 mg	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	1 1/2-0-0			
43	Y/5/I/18	NY. YU		1	39	50	TBC	MERIMAC 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
44	Y/57/XII/17	BP. YL	1		42	62	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
45	D/6/I/18	NN. DW		1	21	39	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			

								ETHAMBUTOL 500 mg	1 1/2-0-0			
								NEOTIBI	0-0-2			
46	R/94/IX/18	BP.RKN	1		43	60	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
47	SU/120/VIII/17	BP.SC	1		43	76	TBC	INHA 400	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
48	W/61/X/17	BP.WD	1		22	56	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
49	SI/24/XII/17	NY.SI		1	66	50,5	TBC	ETHAMBUTOL 500 mg	2-0-0	1	1	1
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
								RIFAMPICIN 450 mg	1-0-0			
								INH 400	1-0-0			
50	A/204/XI/17	NY.AT		1	23	51	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
51	E/37/IV/17	NY.ED		1	42	66	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INH 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
52	SU/141/IX/17	BP.SU	1		66	65	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INH 400	1-0-0			

53	SE/5/XI/18	NY.SM		1	75	27	TBC	INH 300	1-0-0	1	1	1
								TIBITOL 500	1-0-0			
54	SU/15/I/18	BP.SBR	1		61	70	TBC	INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0	1	1	1
								NEOTIBI 500	0-0-3			
55	Y/38/VII/17	NY.YNT		1	33	72	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
56	B/35/VI/17	BP.BS	1		65	62	TBC	RIFAMPICIN 150 MG	1-0-0	1	1	1
								INH 100 MG	1-0-0			
								ETHAMBUTOL 500 mg	0-0-2			
57	E/16/XI/18	NY.EN		1	51	36,5	TBC	RIFAMPICIN 300MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
58	SU/52/II/18	BP.SPR	1		41	52	TBC	RIFASTAR 30 MG	3-0-0	1	1	1
59	N/93/XI/17	NY.NN		1	33	41	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
60	N/30/III/18	NY.NMY		1	56	42	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			

61	I/9/III/18	BP.IP	1		38	69	TBC	PRO TB 4	4-0-0	1	1	1
62	Y/20/III/18	BP.YM	1		56	58	TBC	MERIMAC 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	0-2-0			
								NEOTIBI 500	0-0-3			
63	SU/35/II/18	BP.SL	1		44	52	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
64	A/42/III/18	NY.AS		1	57	51	TBC	RIFASTAR	3-0-0	1	1	1
65	E/15/II/17	NY.ERN		1	42	71	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
66	SE/6/III/18	NN.SI		1	22	40,5	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								RIFAMPICIN 450 mg	1-0-0			
67	E/17/II/18	NY.EE		1	25	45	TBC	RIFASTAR	3-0-0	1	1	1
68	A/64/III/18	NY.AH		1	43	60	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
69	P/15/IV/18	BP.PL	1		71	40	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			

								PYRAZINAMIDE 500 mg	0-0-2			
70	SR/32/IV/18	NY.SHI		1	41	62	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								TB VIT 6	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
71	E/28/IV/18	NY.EW		1	31	33,5	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-2-0			
72	SI/4/IV/18	NY.SWI		1	64	44	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300 mg	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
73	H/20/III/18	SDR.HSN	1		23	67	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
74	K/23/II/18	BP.KDT	1		42	62	TBC	RIFASTAR	4-0-0	1	1	1
75	MU/35/IV/17	NY.MLY		1	49	31	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
76	G/13/III/18	BP.GAW	1		29	55	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
77	R/23/XI/18	BP.RW	1		60	47	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1

								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	0-2-0			
								PYRAZINAMIDE 500 mg	0-0-2			
78	W/14/III/18	NY.WA		1	27	51	TBC	RIFASTAR	3-0-0	1	1	1
79	D/34/IV/18	NY.DI		1	21	51	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
80	SR/25/III/18	NY.SWY		1	52	59	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	0-0-2			
								PYRAZINAMIDE 500 mg	0-0-3			
81	SU/95/V/18	BP.SPM	1		54	40,5	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
82	MA/21/V/18	NY.MY		1	55	60	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
83	B/30/II/18	NN.BRL		1	18	45	TBC	RIFASTAR	3-0-0	1	1	1
84	ME/2/XII/17	NY.MLT		1	75	46	TBC	MERIMAC 450 mg	1-0-0	1	1	1
								INH 300MG	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
85	D/56/V/18	BP.DJ	1		49	52	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1

								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
86	D/6/II/18	NY.DA		1	21	39	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
87	N/45/V/18	NN.NBL		1	14	35	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								NEOTIBI 500	2-0-0			
88	M/5/VI/18	NY.MKM		1	51	36	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2			
89	SA/30/IV/18	BP.SS	1		60	42	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								NEOTIBI 500	0-0-2			
90	J/26/VI/18	BP.JI	1		44	75	TBC	PYRAZINAMIDE 500 mg	0-0-3	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
								INHA 400	1-0-0			
91	A/98/V/18	AN.AA		1	18	45	TBC	RIFASTAR	3-0-0	1	1	1
92	H/45/VI/18	NY.HSF		1	49	60	TBC	RIFASTAR	4-0-0	1	1	1
93	SU/118/VI/18	NY.SGT		1	44	55	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			

							TIBITOL	2-0-0				
							NEOTIBI 500	0-0-3				
94	H/43/VI/28	BP.HS	1		43	61	TBC	RIFASTAR	2-0-0	1	1	1
95	A/119/VI/18	BP.AR	1		34	44	TBC	PRO TB 4	2-0-0	1	1	1
96	D/61/VI/18	BP.DPA	1		22	61	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
							INHA 400	1-0-0				
							ETHAMBUTOL 500 mg	2-0-0				
97	S/16/V/18	BP.SLW	1		47	58	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
							INHA 400	1-0-0				
							ETHAMBUTOL 500 mg	0-0-2				
98	SU/6/I/18	BP.SWD	1		58	65	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
							INHA 400	1-0-0				
							ETHAMBUTOL 500 mg	2-0-0				
99	D/77/VII/18	NN.DP		1	21	43	TBC	RIFASTAR	3-0-0	1	1	1
100	J/29/VII/18	NY.JMI		1	40	64	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
							INHA 400	1-0-0				
							ETHAMBUTOL 500 mg	2-0-0				
101	L/29/VI/18	NN.LC		1	31	68	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
							INHA 400	1-0-0				
							ETHAMBUTOL 500 mg	2-0-0				
							NEOTIBI 500	0-0-1 1/2				
102	Q/2/VII/18	NY.QL		1	35	40	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
							INH 300 MG	1-0-0				

								ETHAMBUTOL 500 mg	1 1/2-0-0			
103	R/76/VII/18	SDR.RB	1		26	70	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
104	A/120/V/18	NN.AMD		1	18	47	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
								NEOTIBI 500	0-0-2 1/2			
105	MA/33/VIII/18	NY.MR		1	85	32	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
								PYRAZINAMIDE 500 mg	0-0-1 1/2			
106	D/78/VII/18	BP.DJP	1		58	64	TBC	TB VIT 6	1-0-0	1	1	1
								TIBITOL 500	2-0-0			
								NEOTIBI 500	0-0-3			
107	Y/36/VII/18	SDR.YH	1		27	52	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
108	SI/26/VIII/18	NY.SE		1	56	65	TBC	TB VIT 6	1-0-0	1	1	1
								TIBITOL 500	2-0-0			
								NEOTIBI 500	0-0-3			
109	SU/107/VI/18	NY.SPI		1	74	34	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1

								INH 300 MG	1-0-0			
								ETHAMBUTOL 500 mg	1 1/2-0-0			
110	S/28/VIII/18	BP.SLMT	1		70	40	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	0-1 1/2-0			
								PYRAZINAMIDE 500 mg	0-0-2			
111	SI/24/XII/17	NY.SY		1	65	50,5	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
112	I/24/IV/18	SDR.IT	1		15	36,5	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
113	A/148/VIII/18	SDR.AG	1		19	35	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								PYRAZINAMIDE 500 mg	0-2 1/2-0			
114	J/34/VIII/18	BP.JMN	1		60	66	TBC	PRO TB 4	4-0-0	1	1	1
115	I/26/IV/18	BP.ISW	1		58	36	TBC	PRO TB 4	2-0-0	1	1	1
116	SR/51/VIII/18	NY.SMN		1	44	70	TBC	PRO TB 4	4-0-0	1	1	1
117	R/86/VIII/18	BP.RKY	1		54	61	TBC	PRO TB 4	4-0-0	1	1	1
118	SR/32/VII/18	NY.SAN		1	60	58,5	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								TB VIT 6	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
119	F/40/IX/18	BP.FS	1		51	55	TBC	PRO TB 4	3-0-0	1	1	1
120	I/37/IX/18	NY. IA		1	32	65	TBC	RIFASTAR	4-0-0	1	1	1

121	N/32/III/18	NY.NE		1	38	56	TBC	INHA 400	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	0-2-0			
								NEOTIBI 500	0-0-3			
122	R/87/VIII/18	BP.RKJ	1		70	44	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	0-2-0			
								NEOTIBI 500	0-0-2			
123	I/36/VII/18	NN.IY		1	21	44	TBC	PRO TB 4	3-0-0	1	1	1
124	SA/22/V/17	BP.SDN	1		61	54	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-2 1/2			
125	SU/154/IX/18	BP.STR	1		58	68	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
126	T/68/IX/18	NN.TH		1	16	55	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	0-0-3			
127	A/170/IX/18	NY.ADT		1	75	31	TBC	RIFAMPICIN 300 MG	1-0-0	1	1	1
								INH 300 MG	1-0-0			
								ETHAMBUTOL 500 mg	0-1-0			

								PYRAZINAMIDE 500 mg	0-0-1 1/2			
128	N/70/IX/18	BP.NA	1		25	48	TBC	PRO TB 4	3-0-0	1	1	1
129	A/162/IX/18	BP.ASW	1		54	60	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
130	J/39/IX/18	BP.JS	1		59	60	TBC	RIFASTAR	3-0-0	1	1	1
131	J/41/IX/18	BP.JMS	1		38	76	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	0-0-2			
								PYRAZINAMIDE 500 mg	0-0-3			
132	R/104/IX/18	SDR.RN	1		26	61	TBC	RIFASTAR	3-0-0	1	1	1
133	E/61/X/18	BP.EB	1		23	55	TBC	RIFASTAR	3-0-0	1	1	1
134	MA/56/X/18	BP.MRJ	1		47	56	TBC	RIFAMPICIN 600 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
								PYRAZINAMIDE 500 mg	3-0-0			
135	D/110/X/18	BP.DR	1		34	45	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								PYRAZINAMIDE 500 mg	0-2-0			
								TIBITOL	2-0-0			
136	H/70/X/18	BP.HRMN	1		45	53	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	0-2-0			

								PYRAZINAMIDE 500 mg	0-0-2 1/2			
137	K/33/VI/18	BP.KRN	1		60	46,5	TBC	INHA 400	1-0-0	1	1	1
								ETHAMBUTOL 500 mg	2-0-0			
								NEOTIBI 500	0-2-0			
138	R/112/XI/18	NY.RL		1	22	46	TBC	RIFASTAR	3-0-0	1	1	1
139	R/97/IX/18	BP.RSD	1		37	46	TBC	RIFAMPICIN 150 MG	1-0-0	1	1	1
140	R/92/IX/18	SDR.RDN	1		34	65	TBC	RIFASTAR	4-0-0	1	1	1
141	N/82/XI/18	NN.NA		1	13	30	TBC	RIFAMPICIN 300MG	1-0-0	1	1	1
								INH 300	1-0-0			
								NEOTIBI 500	0-1-0			
142	N/87/XII/18	NN.NK		1	12	39	TBC	MERIMAC 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
143	N/91/XII/18	NN.NLA		1	11	28,5	TBC	RIFAMPICIN 300MG	1-0-0	1	1	1
								INH 300	1-0-0			
								NEOTIBI 500	0-2-0			
144	A/164/IX/8	NN.AD		1	22	43	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								PYRAZINAMIDE 500 mg	2-0-0			
								ETHAMBUTOL 500 mg	2-0-0			
145	W/42/XI/18	NY.WP		1	41	55	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								PYRAZINAMIDE 500 mg	0-2 1/2-0			
								ETHAMBUTOL 500 mg	2-0-0			

146	SU/88/XI/18	NY.SRH		1	52	56,5	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INHA 400	1-0-0			
								ETHAMBUTOL 500 mg	0-0-2			
								PYRAZINAMIDE 500 mg	0-0-3			
147	T/82/II/18	NY.TS		1	28	36	TBC	PRO TB 4	3-0-0	1	1	1
148	R/98/XI/18	NY.RAP		1	45	43	TBC	RIFAMPICIN 450 mg	1-0-0	1	1	1
								INH 300	1-0-0			
								ETHAMBUTOL 500 mg	2-0-0			